More on JAZZ
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $230.25 |
|
|||
| Open | $230.25 | ||||
| 52 Wk High | $160.00 | ||||
| 52 Wk Low | $95.80 | ||||
| Day High | $230.25 | ||||
| Day Low | $230.25 | ||||
| P/E | 42.80 | ||||
| EPS | $5.38 | ||||
| Volume | 2,301 | ||||
- Form 4 Jazz Pharmaceuticals For: Jun 15 Filed by: Smith Mark Douglas
- Jazz Pharmaceuticals and AbCellera ink antibody research deal
- Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
- Jazz Pharmaceuticals presents Xywav sleep disorder data at SLEEP 2026 conference
- Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Nar
- Form 144 Jazz Pharmaceuticals Filed by: Smith Mark Douglas
- Form 4 Jazz Pharmaceuticals For: Jun 10 Filed by: Patil Neena M
- Jazz's Zepzelca fails late-stage lung cancer trial
- Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
- Form 144 Jazz Pharmaceuticals Filed by: Patil Neena M
Entities mentioned with JAZZ
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
